查看购物车
  • Traditional Chinese
  • English
  • Japanese
胃癌市场:KOL的洞察
市场调查报告书
商品编码
1751659

胃癌市场:KOL的洞察

KOL Insight - Gastric Cancer
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

这份全面的报告汇集了12位美国和欧洲关键意见领袖 (KOL) 对胃癌 (GC) 治疗现状和未来的见解。报告探讨了曲妥珠单抗和Enhertu等HER2标靶疗法的持续发展，评估了Keytruda、Opdivo和Tevinbra等免疫肿瘤药物的临床和商业意义，并评估了zolbetuximab、bemarituzumab和zanidatamab等新兴疗法的未来潜力。报告探讨了GC管理中的关键课题、生物标记在指导治疗中日益增强的作用，以及对新型联合治疗策略的预期。报告将深入分析已核准和正在研发的疗法，并结合专家对临床试验结果和未来治疗趋势的见解。

关键问题

  • 1.目前胃癌治疗有哪些未被满足的需求？
  • 2.胃癌患者常见的第一线和第二线治疗有哪些？
  • 3.HER2状态如何影响胃癌的治疗选择？
  • 4.Opdivo、Keytruda、Tevinbra、Bayloi等新核准的药物如何影响治疗策略？
  • 5.哪一种免疫肿瘤学方法在胃癌治疗中最具前景？
  • 6.生物标记如何用于指导胃癌治疗？
  • 7.专家对贝马利珠单抗和佐贝妥昔单抗等新型标靶疗法有何看法？
  • 8.您预期未来3到5年胃癌治疗模式将如何改变？

领导品牌

  • ARX788
  • BAVENCIO(Avelumab)
  • bemaritsuzumabu
  • seraraserutibu
  • CYRAMZA(Ramucirumab)
  • domachinosutatto
  • enherutu(Trastuzumab·derukusutekan)
  • ebopaseputo
  • Herceptin(Trastuzumab)
  • imufinji(Durvalumab)
  • ipataseruchibu
  • yaboi(Ipilimumab)
  • KEYTRUDA(Pembrolizumab)
  • LENVIMA(Lenvatinib)
  • Margetuximab
  • Ontruzant(Trastuzumab)
  • Opdivo(Nivolumab)
  • riratorimabu
  • rimubumabu(katumakisomabu)
  • rechifanrimabu
  • ruburaka(rukaparibu)
  • suchibaga(Regorafenib)
  • teboterimabu
  • TECENTRIQ(Atezolizumab)
  • tebinbura(chisurizumabu)
  • tsukisa(tsukachinibu)
  • bairoi(zorubetsukishimabu)
  • yaboi(Ipilimumab)
  • zanidatamabu

研究方法：

"治疗趋势" 报告透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，探讨关键疾病领域的当前和未来治疗前景。 KOL 的筛选标准非常严格，包括全球声誉、临床专业知识以及在其治疗领域的影响力。每次访谈都配有精心设计的讨论指南。这些指南由我们与 KOL 合作开发，并由行业专家进行同行评审，以确保所提问题全面且与当前市场动态相关。在每份报告发布后，我们会持续进行12个月的市场监测，并及时向您提供 KOL 提供的重要新闻事件、市场变化和市场发展的最新资讯。

我们的报告有何特别之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供详细且切实可行的洞察。我们拥有深厚的行业知识，能够为您提供相关且有价值的洞察，帮助您掌握新兴趋势，有​​效应对复杂课题。我们的报告以广泛的研究以及来自顶尖专家和关键意见领袖 (KOL) 的独立、公正的见解为后盾，能够提供您所需的准确性和可靠性。独家访谈和数据，以及持续的市场监测，确保您全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域，包含包括关键意见领袖洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入和其他领域问题的看法，使您能够做出更明智的数据驱动决策，从而在快速变化的行业中保持竞争力。

简介目录

This comprehensive report delves into the current and future landscape of gastric cancer (GC) treatments, offering insights from 12 key opinion leaders (KOLs) across the US and Europe. It examines the evolving roles of HER2-targeted therapies such as trastuzumab and Enhertu, assesses the clinical and commercial implications of immuno-oncology agents including Keytruda, Opdivo, and Tevimbra, and evaluates the promise of emerging therapies like zolbetuximab, bemarituzumab, and zanidatamab. The report explores key challenges in GC management, the growing role of biomarkers in guiding treatment, and expectations for new combination strategies. Gain a detailed understanding of both approved and pipeline therapies, supported by expert insights on trial outcomes and future treatment dynamics.

Key Questions Answered:

  • 1. What are the biggest unmet needs in gastric cancer treatment today?
  • 2. How are gastric cancer patients typically treated in first- and second-line settings?
  • 3. How is HER2 status influencing therapy selection in gastric cancer?
  • 4. What impact have new approvals like Opdivo, Keytruda, Tevimbra, and Vyloy had on treatment strategies?
  • 5. Which immuno-oncology approaches show the most promise in gastric cancer?
  • 6. How are biomarkers being used to guide treatment decisions in GC?
  • 7. What are expert views on emerging targeted therapies like bemarituzumab and zolbetuximab?
  • 8. How is the gastric cancer treatment landscape expected to evolve over the next 3-5 years?

Key Brands:

  • ARX788
  • Bavencio (avelumab)
  • Bemarituzumab
  • Ceralasertib
  • Cyramza (ramucirumab)
  • Domatinostat
  • Enhertu (trastuzumab deruxtecan)
  • Evorpacept
  • Herceptin (trastuzumab)
  • Imfinzi (durvalumab)
  • Ipatasertib
  • Yervoy (ipilimumab)
  • Keytruda (pembrolizumab)
  • Lenvima (lenvatinib)
  • Margetuximab
  • Ontruzant (trastuzumab)
  • Opdivo (nivolumab)
  • Relatlimab
  • Removab (catumaxomab)
  • Retifanlimab
  • Rubraca (rucaparib)
  • Stivarga (regorafenib)
  • Tebotelimab
  • Tecentriq (atezolizumab)
  • Tevimbra (tislelizumab)
  • Tukysa (tucatinib)
  • Vyloy (zolbetuximab)
  • Yervoy (ipilimumab)
  • Zanidatamab

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.